World's Best Scientists 2026 revealed!
Timo Vesikari

Timo Vesikari

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Immunology 89 1103 1001 7 7 437 35812
Medicine 89 12523 11782 140 129 443 35934

Timo Vesikari publications per year

The chart shows the history of publications by Timo Vesikari between 1968 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Timo Vesikari published across 58 years, from 1968 to 2025, averaging 7.6 papers a year. Output peaked at 26 publications in 2016. 1 of the 439 publications appeared in the last two years.

No. of publications
5 10 15 20 25
Bar chart. Horizontal axis: year, 1968 to 2025. Vertical axis: number of publications, 0 to 26. Peak 26 publications in 2016. 1968: 1 publication 1969: 3 publications 1970: 1 publication 1971: 4 publications 1972: 5 publications 1973: 2 publications 1974: 2 publications 1975: 1 publication 1976: 0 publications 1977: 0 publications 1978: 3 publications 1979: 4 publications 1980: 4 publications 1981: 5 publications 1982: 4 publications 1983: 4 publications 1984: 8 publications 1985: 11 publications 1986: 6 publications 1987: 9 publications 1988: 5 publications 1989: 4 publications 1990: 5 publications 1991: 5 publications 1992: 6 publications 1993: 4 publications 1994: 7 publications 1995: 7 publications 1996: 5 publications 1997: 6 publications 1998: 5 publications 1999: 10 publications 2000: 2 publications 2001: 2 publications 2002: 2 publications 2003: 1 publication 2004: 3 publications 2005: 8 publications 2006: 12 publications 2007: 11 publications 2008: 17 publications 2009: 17 publications 2010: 17 publications 2011: 18 publications 2012: 24 publications 2013: 20 publications 2014: 14 publications 2015: 23 publications 2016: 26 publications 2017: 13 publications 2018: 16 publications 2019: 13 publications 2020: 18 publications 2021: 10 publications 2022: 5 publications 2023: 0 publications 2024: 0 publications 2025: 1 publication
1968 2025

439 publications in total across all disciplines

View publications per year as a table
Timo Vesikari: publications per year, 1968 to 2025
Year Publications
1968 1
1969 3
1970 1
1971 4
1972 5
1973 2
1974 2
1975 1
1976 0
1977 0
1978 3
1979 4
1980 4
1981 5
1982 4
1983 4
1984 8
1985 11
1986 6
1987 9
1988 5
1989 4
1990 5
1991 5
1992 6
1993 4
1994 7
1995 7
1996 5
1997 6
1998 5
1999 10
2000 2
2001 2
2002 2
2003 1
2004 3
2005 8
2006 12
2007 11
2008 17
2009 17
2010 17
2011 18
2012 24
2013 20
2014 14
2015 23
2016 26
2017 13
2018 16
2019 13
2020 18
2021 10
2022 5
2023 0
2024 0
2025 1
Total 439
Download as CSV

Timo Vesikari publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Timo Vesikari sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 432–441 publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 437 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178
212–221 158
222–231 168
232–241 159
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69
362–371 76
372–381 71
382–391 71
392–401 62
402–411 54
412–421 41
422–431 63
432–441 53 437
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100
Download as CSV

Timo Vesikari D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Timo Vesikari sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 88–89 D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 89 D-Index — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188
52–53 177
54–55 155
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172
70–71 199
72–73 184
74–75 133
76–77 163
78–79 127
80–81 121
82–83 125
84–85 121
86–87 102
88–89 96 89
90–91 75
92–93 72
94–95 74
96–97 66
98–99 68
100–101 49
102–103 60
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96
Download as CSV

Overview

Timo Vesikari is affiliated with Tampere University in Finland and has contributed extensively to the fields of Medicine and Immunology and Microbiology. Their research encompasses a variety of topics primarily centered on bacterial infections, vaccines, and respiratory infections. The scientist's work also covers influenza virus research, viral gastroenteritis, viral immunology, and congenital diaphragmatic hernia studies.

Their research output includes numerous publications in high-impact journals, reflecting a focus on clinical immunogenicity, vaccine safety, and infectious disease epidemiology. The principal venues for their work include Human Vaccines & Immunotherapeutics, Vaccine, The Journal of Infectious Diseases, The Lancet Infectious Diseases, and Diabetes.

  • Recent papers:
  • Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study, 2020, Human Vaccines & Immunotherapeutics
  • Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings, 2022, The Journal of Infectious Diseases
  • Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study, 2022, Vaccine
  • Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age, 2020, Human Vaccines & Immunotherapeutics
  • Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months, 2021, Vaccine

The main fields of study addressed by their publications include Medicine, with 21 works, and Immunology and Microbiology, represented in 6 publications. More specialized subfields of their research include Epidemiology (14 publications), Microbiology (6), Infectious Diseases (2), Cardiology and Cardiovascular Medicine (2), and Surgery (1).

The main research topics featured in their work are:

  • Bacterial Infections and Vaccines
  • Pneumonia and Respiratory Infections
  • Influenza Virus Research Studies
  • Respiratory viral infections research
  • Viral gastroenteritis research and epidemiology
  • Viral Infections and Immunology Research
  • Congenital Diaphragmatic Hernia Studies

Frequent collaborators in their research include John L. Perez with four shared publications, and others such as Aino Forstén, Joanne M. Langley, Chris Webber, and Marie Van der Wielen, each with two collaborations.

Best Publications

  • Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

    Guillermo M. Ruiz-Palacios;Irene Pérez-Schael;F. Raúl Velázquez;Hector Abate

  • Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine

    Timo Vesikari;David O Matson;Penelope Dennehy;Pierre Van Damme

  • Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

    Himal Lal;Anthony L. Cunningham;Olivier Godeaux;Roman Chlibek

  • Live attenuated versus inactivated influenza vaccine in infants and young children.

    Robert B. Belshe;Kathryn M. Edwards;Timo Vesikari;Steven V. Black

  • Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

    A. L. Cunningham;H. Lal;M. Kovac;R. Chlibek

  • Lactic Acid Bacteria in the Treatment of Acute Rotavirus Gastroenteritis

    Heli Majamaa;Erika Isolauri;Maija Saxelin;Timo Vesikari

  • Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children.

    Aino-Vieno Shornikova;Ivan A. Casas;Erika Isolauri;Hannu Mykkänen

  • Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50–59 Years

    Kenneth E. Schmader;Myron J. Levin;John W. Gnann;John W. Gnann;Shelly A. McNeil

  • Burden of rotavirus disease in European Union countries.

    Montse Soriano-Gabarró;Jacek Mrukowicz;Timo Vesikari;Thomas Verstraeten

  • Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG

    Erika Isolauri;Jaana Joensuu;Hanna Suomalainen;Mari Luomala

  • PROTECTION OF INFANTS AGAINST ROTAVIRUS DIARRHOEA BY RIT 4237 ATTENUATED BOVINE ROTAVIRUS STRAIN VACCINE

    Timo Vesikari;Erika Isolauri;Eric D'Hondt;Andrée Delem

  • Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children

    Steven Black;Uwe Nicolay;Timo Vesikari;Markus Knuf

  • Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis.

    Aino-Vieno Shornikova;Ivan A. Casas;Hannu Mykkänen;Eeva Salo

  • Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children

    Timo Vesikari;Markus Knuf;Peter Wutzler;Aino Karvonen

  • Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis

    Jaana Joensuu;Eeva Koskenniemi;Xiao-Li Pang;Timo Vesikari

  • Viable versus inactivated lactobacillus strain GG in acute rotavirus diarrhoea.

    M Kaila;E Isolauri;M Saxelin;H Arvilommi

  • Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

    Timo Vesikari;Susanna Esposito;Roman Prymula;Ellen Ypma

  • Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

    Timo Vesikari;Jacek Wysocki;Bertrand Chevallier;Aino Karvonen

  • Human caliciviruses in acute gastroenteritis of young children in the community.

    Xiao-Li Pang;Shinjiro Honma;Shuji Nakata;Timo Vesikari

  • Efficacy of RIX4414 Live Attenuated Human Rotavirus Vaccine in Finnish Infants

    Timo Vesikari;Aino Karvonen;Leena Puustinen;Shang-Qin Zeng

  • Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.

    Timo Vesikari;Michele Pellegrini;Aino Karvonen;Nicola Groth

  • Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland

    Maria Hemming;Sirpa Räsänen;Leena Huhti;Minna Paloniemi

  • One-step quantitative RT-PCR for the detection of rotavirus in acute gastroenteritis.

    S.-Q. Zeng;A. Halkosalo;M. Salminen;E.D. Szakal

  • A trial in the Karelian Republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhoea

    A V Shornikova;E Isolauri;L Burkanova;S Lukovnikova

Frequent Co-Authors

Markku Mäki
Markku Mäki Tampere University
Albert Z. Kapikian
Albert Z. Kapikian National Institutes of Health
Erika Isolauri
Erika Isolauri University of Turku
Myron J. Levin
Myron J. Levin University of Colorado Anschutz Medical Campus
Janet E. McElhaney
Janet E. McElhaney Health Sciences North
Heikki Hyöty
Heikki Hyöty Tampere University
Carlo Giaquinto
Carlo Giaquinto University of Padua
Anthony L. Cunningham
Anthony L. Cunningham University of Sydney
Shelly A. McNeil
Shelly A. McNeil Dalhousie University
Max Ciarlet
Max Ciarlet Novartis (Switzerland)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in immunology, exploring related healthcare degrees can broaden career opportunities. Many turn to nursing pathways, which complement immunological knowledge with practical patient care skills. Programs like the accelerated fnp program offer a fast track to becoming a Family Nurse Practitioner, combining advanced clinical training with immunology foundations.

Non-nurses looking to enter the field can consider online adn programs for non nurses, which allow individuals without a nursing background to earn their Associate Degree in Nursing efficiently. These programs provide essential healthcare knowledge applicable to immunology-related roles.

For those seeking quicker entry, accelerated nursing programs are designed to fast-track registered nurse status, ideal for leveraging immunology studies in clinical practice.

Additionally, lpn programs easy to get into provide accessible pathways into nursing, offering foundational skills valuable in immunology-related healthcare support roles. Pursuing these diverse educational paths can enhance both knowledge and employment prospects in immunology and related medical fields.

Best Scientists Citing Timo Vesikari

Trending Scientists

Recently Published Articles